Drug intelligence / Profile preview

BR1018A + BR1018C

Development stage: Unknown
Lead developer: Boryung
Modality: Small Molecules

Overview

BR1018A + BR1018C is an investigational **combination drug** being developed by Boryung Corp. for the treatment of **essential hypertension** and **primary hypercholesterolemia**. It comprises two small-molecule agents: BR1018A and BR1018C, co-administered as part of combination therapy strategies targeting cardiovascular and metabolic disorders. The detailed structures, precise mechanisms of action, and individual components for BR1018A and BR1018C have not been publicly disclosed. Current clinical studies are focused on evaluating the efficacy and safety of this combination in the specified indications.

Beyond the preview

Go deeper on BR1018A + BR1018C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR1018A + BR1018C.

Explore the full profile